<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Sun, 11 Jan 2026 07:00:09 +0000</lastBuildDate>
    <item>
      <title>#1 [90/100] Is proton therapy a new standard of care for oropharyngeal cancer?</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41519583/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41519583/</guid>
      <dc:creator>Jensen K, Grau C</dc:creator>
      <pubDate>Sat, 10 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;ðŸ”¥ CRITICAL - Score: 90/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The paper discusses proton therapy as a potential new standard of care for oropharyngeal cancer, published in a top-tier journal (Lancet), indicating significant clinical implications and the potential to change treatment paradigms.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Jensen K, Grau C&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Lancet (London, England) | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/S0140-6736(25)02639-X'&gt;10.1016/S0140-6736(25)02639-X&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-10&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41519583/'&gt;41519583&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#2 [75/100] Auditory Preservation in Nasopharyngeal Carcinoma: Comparison of Proton and Photon Radiotherapy.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41503873/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41503873/</guid>
      <dc:creator>Lien KH, Lin CY, Chen PY, Chang JT, Chen TY, Hung SP, Lee CH, Yap WK, Hsieh CE, Hsu CL, et al.</dc:creator>
      <pubDate>Thu, 08 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents a prospective matched cohort design comparing two radiotherapy techniques in a significant patient population, with important implications for auditory preservation in nasopharyngeal carcinoma, although it does not reach the level of a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Lien KH, Lin CY, Chen PY, Chang JT, Chen TY, Hung SP, Lee CH, Yap WK, Hsieh CE, Hsu CL, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/ohn.70113'&gt;10.1002/ohn.70113&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-08&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41503873/'&gt;41503873&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To compare cochlear dose and hearing outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) in patients with nasopharyngeal carcinoma (NPC). STUDY DESIGN: Prospective matched cohorts. SETTING: Tertiary academic center. METHODS: A total of 180 newly diagnosed, treatment-naive NPC patients receiving definitive radiotherapy between 2023 and 2025 were enrolled. Patients were 1:1 matched by sex, age, and disease stage, and assigned to IMPT (nâ€‰=â€‰90) or VMAT (nâ€‰=â€‰90). Mean cochlear dose was recorded. Audiological evaluations, including pure-tone audiometry (PTA), air-bone gap, and word recognition score, were performed before and after treatment. RESULTS: IMPT delivered significantly lower mean doses to the ipsilateral (47.51 vs 56.82â€‰Gy, Pâ€‰&lt;â€‰.001; 95% CI: -14.27 to -4.35) and contralateral cochlea (30.79 vs 45.71â€‰Gy, Pâ€‰&lt;â€‰.001; 95% CI: -18.93 to -10.91). Based on each patient's most recent audiometric assessment (median follow-up, 12.1 months; range, 7.5-19.5 months), IMPT demonstrated better average PTA thresholds than VMAT (33.72 vs 42.00â€‰dB; Pâ€‰=â€‰.016; 95% CI, -14.91 to -1.65), superior high-frequency hearing at 2 to 8â€‰kHz (37.94 vs 53.82â€‰dB; Pâ€‰&lt;â€‰.001; 95% CI, -23.69 to -8.07), lower air-bone gap (5.67 vs 10.62â€‰dB; Pâ€‰&lt;â€‰.001; 95% CI, -6.80 to -3.10), and higher word recognition scores (96.67% vs 94.00%; Pâ€‰=â€‰.039; 95% CI, 0.14-5.20), with less bone conduction loss at 1 to 4â€‰kHz. CONCLUSION: IMPT reduces cochlear dose compared to VMAT, resulting in better hearing preservation and suggesting its potential to minimize ototoxicity in NPC patients.</description>
    </item>
    <item>
      <title>#3 [70/100] Improved Survival of HPV-Related Sinonasal Squamous Cell Carcinoma With Chemoradiation Treatment.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41503790/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41503790/</guid>
      <dc:creator>Oliver JR, Wang NC, Alapati R, Attwood E, Amanian A, Bur AM, Beahm DD</dc:creator>
      <pubDate>Thu, 08 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study utilizes a large dataset from the National Cancer Database and employs robust methodology to analyze treatment outcomes in HPV-related sinonasal squamous cell carcinoma, providing important insights that could influence clinical practice.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Oliver JR, Wang NC, Alapati R, Attwood E, Amanian A, Bur AM, Beahm DD&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Head &amp; neck | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/hed.70156'&gt;10.1002/hed.70156&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-08&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41503790/'&gt;41503790&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: Human papillomavirus-related (HPV+) sinonasal squamous cell carcinoma (SNSCC) is associated with improved overall survival (OS) compared to similarly staged HPV-negative SNSCC. However, data on treatment-specific outcomes remain limited. METHODS: We analyzed the National Cancer Database (NCDB) for all SNSCC cases diagnosed between 2010 and 2017 with available HPV testing data. Prognostically significant variables were identified via multivariable Cox regression. Propensity score-matched cohorts were then created, matching HPV-positive and HPV-negative patients exactly by treatment modality and other significant prognostic factors. The association between HPV status and 5-year OS was assessed across treatment strategies. RESULTS: A total of 1697 HPV-tested SNSCC cases were identified; 551 (32.5%) were HPV+. Multivariable Cox regression showed that HPV status, age, comorbidity score, tumor size, lymphovascular invasion, stage, and surgical margin status were significantly associated with outcomes. Within the propensity score-matched cohort, HPV positivity was significantly associated with improved OS among patients treated with chemoradiation (HRâ€‰=â€‰0.55; 95% CIâ€‰=â€‰0.35-0.87, pâ€‰=â€‰0.01). No survival benefit was observed in patients treated with surgery alone (HRâ€‰=â€‰0.85; 95% CIâ€‰=â€‰0.35-2.04, pâ€‰=â€‰0.71), surgery with radiation (HRâ€‰=â€‰1.38; 95% CIâ€‰=â€‰0.64-3.02, pâ€‰=â€‰0.41), radiation alone (HRâ€‰=â€‰0.40; 95% CIâ€‰=â€‰0.11-1.41, pâ€‰=â€‰0.16), or in the combined group of these three treatment strategies (HRâ€‰=â€‰0.97; 95% CIâ€‰=â€‰0.57-1.62, pâ€‰=â€‰0.90). CONCLUSION: These findings suggest that HPV+ SNSCC may be particularly sensitive to chemoradiation. Routine HPV testing may be warranted to investigate if tailored treatment approaches focusing on chemoradiation may benefit patients with HPV+ SNSCC.</description>
    </item>
    <item>
      <title>#4 [70/100] Efficacy and safety of immunotherapy monotherapy versus combination regimens in recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41495509/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41495509/</guid>
      <dc:creator>Zhang A, Cui Y</dc:creator>
      <pubDate>Tue, 06 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis addresses an important clinical question regarding the efficacy and safety of immunotherapy regimens in recurrent/metastatic head and neck squamous cell carcinoma, providing valuable insights that could influence treatment decisions, though it is not a primary study or a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Zhang A, Cui Y&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1007/s00405-025-09926-4'&gt;10.1007/s00405-025-09926-4&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-06&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41495509/'&gt;41495509&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#5 [70/100] A seven-gene 5-hydroxymethylcytosine signature in circulating cell-free DNA for prognostic stratification of nasopharyngeal carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41500466/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41500466/</guid>
      <dc:creator>Chen B, Wang D, Huang J, Yu S, Fang S, Chen C, Wang J, Pan J, Lin S, Guo Q, et al.</dc:creator>
      <pubDate>Mon, 05 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents a large prospective analysis with a novel prognostic biomarker in nasopharyngeal carcinoma, which could have significant clinical implications for patient stratification, although it does not provide direct evidence of practice change or survival benefit.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Chen B, Wang D, Huang J, Yu S, Fang S, Chen C, Wang J, Pan J, Lin S, Guo Q, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.radonc.2026.111366'&gt;10.1016/j.radonc.2026.111366&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-05&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41500466/'&gt;41500466&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: Circulating cell-free DNA (cfDNA) 5-hydroxymethylcytosine (5hmC) is a promising epigenetic biomarker in cancer. Its prognostic role in nasopharyngeal carcinoma (NPC), however, remains unclear. METHODS: Genome-wide 5hmC profiling was conducted using 5hmC-Seal sequencing on cfDNA from 174 newly diagnosed NPC patients. Patients were randomly assigned to training (nâ€¯=â€¯105) and test (nâ€¯=â€¯69) sets. Differential analysis was performed by survival outcome, EBV status, and tumor stage. The primary endpoint was overall survival (OS); the secondary endpoint was event-free survival (EFS). A prognostic score based on a seven-gene 5hmC signature was developed using LASSO-Cox regression in the training set and validated in the test cohort. A nomogram integrating the 5hmC score, tumor stage, and EBV status was constructed. Model performance was assessed via Kaplan-Meier survival analysis, time-dependent ROC curves, calibration plots, and decision curve analysis (DCA). RESULTS: Marked 5hmC differences were detected between survivors and non-survivors. The 5hmC score stratified OS with AUCs of 0.83 (3-year) and 0.87 (5-year) in the training set and 0.78 (3-year) and 0.80 (5-year) in the test set, and remained predictive across EBV and stage subgroups. The integrated nomogram demonstrated robust calibration and offered the greatest net clinical benefit in DCA, with a 5-year C-index of 0.796. CONCLUSIONS: cfDNA 5hmC profiling enables noninvasive prognostic risk stratification in NPC. The proposed model may support personalized treatment planning and long-term management.</description>
    </item>
    <item>
      <title>#6 [70/100] Prognostic heterogeneity of HPV-associated oropharyngeal cancer in a Taiwanese population.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41492174/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41492174/</guid>
      <dc:creator>Liu PT, Chiang CJ, Yang YW, Lee WC, Hsu WL, Chen TI, Lee HL, Wang CP, Liao LJ, Wang CC, et al.</dc:creator>
      <pubDate>Mon, 05 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study involves a large retrospective cohort of 5,671 patients, providing important insights into the prognostic factors of HPV-associated oropharyngeal cancer, which could inform treatment planning and prognostication, although it is not a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Liu PT, Chiang CJ, Yang YW, Lee WC, Hsu WL, Chen TI, Lee HL, Wang CP, Liao LJ, Wang CC, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; BMC cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1186/s12885-025-15528-4'&gt;10.1186/s12885-025-15528-4&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-05&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41492174/'&gt;41492174&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: Oropharyngeal squamous cell carcinoma (OPSCC) is increasing worldwide, with a well-established link to human papillomavirus (HPV). However, evidence on how lifestyle risk factors-particularly smoking, alcohol consumption, and betel-quid chewing-modify the prognostic impact of HPV-associated disease remains limited, especially in regions with high exposure burden such as Taiwan. Understanding the interplay between viral and lifestyle determinants is essential for accurate prognostication and treatment planning. METHODS: We conducted a retrospective cohort study of 5,671 OPSCC patients using data from the Taiwan Cancer Registry between 2018 and 2021. p16 status was used as a surrogate marker for HPV infection. Overall survival and cancer-specific survival were compared across p16 status, age, sex, tumor location, cancer stage, lifestyle risk factors and treatment pattern using Kaplan-Meier method and multiple Cox models. Treatment-stratified analyses were additionally performed to evaluate whether lifestyle risk factors modified prognosis within p16-positive disease. RESULTS: Overall, 23.2% of OPSCC cases were p16-positive, with substantially higher p16 positivity among females (52.5%) and in tonsillar subsites. p16-positive patients had significantly better 5-year overall survival (69.0%; 95% CI, 66.0%-71.8%) than p16-negative patients (37.9%; 36.1%-39.6%). However, among p16-positive individuals, the presence of multiple lifestyle risk factors markedly attenuated the survival advantage, reducing 5-year overall survival from 78.6% (74.0%-82.5%) in those without lifestyle exposures to 57.6% (52.6%-62.4%) in those with smoking plus other risks. These gradients persisted after multivariable adjustment and across treatment modalities. In contrast, lifestyle risk factors were not independently associated with survival in p16-negative OPSCC, where prognosis was primarily driven by tumor stage, subsite, and treatment. CONCLUSIONS: This nationwide study provides novel evidence that the prognostic benefit associated with p16 positivity is substantially attenuated by multiple lifestyle risk factors. These findings highlight the importance of integrating viral and behavioral determinants into prognostic assessment and treatment planning. They also underscore the need to pair HPV-associated prevention strategies with efforts to reduce tobacco, alcohol, and betel-quid use in regions with high burdens of these exposures.</description>
    </item>
    <item>
      <title>#7 [70/100] The Effect of Rehabilitation Interventions on Trismus in Oral Cancer Patients: A Systematic Review.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41486431/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41486431/</guid>
      <dc:creator>Wang H, An Y, Liu D</dc:creator>
      <pubDate>Sun, 04 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review includes multiple randomized controlled trials and quasi-experimental studies, providing important insights into rehabilitation interventions for trismus in oral cancer patients, which has clinical relevance, though it may not be directly practice-changing.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Wang H, An Y, Liu D&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral diseases | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1111/odi.70185'&gt;10.1111/odi.70185&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-04&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41486431/'&gt;41486431&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To systematically evaluate rehabilitation interventions for oral cancer patients with trismus and clarify effects on trismus. MATERIALS AND METHODS: A comprehensive search for randomized controlled trials and quasi-experimental studies published up to November 28, 2024, was conducted across PubMed, Embase, Cochrane Library, Web of Science, CINAHL, CBM, CNKI, VIP, and Wanfang using the PICOS strategy. The primary outcome was mouth opening distance. Two authors independently assessed risk of bias and methodological quality using the Cochrane Handbook (version 5.1.0) and ROBINS-I. The study protocol was registered with PROSPERO (CRD42024613003). RESULTS: The review included 15 articles, including eight randomized controlled trials and seven quasi-experimental studies. There were variations in the timing and type of rehabilitation. Most interventions started 2-3â€‰weeks post-surgery. Three types of interventions, including exercise training, physical therapy, and speech training, improved trismus. CONCLUSION: Rehabilitation interventions are often used in combination, but the effectiveness of individual interventions remains unclear. Physical therapy has been shown to alleviate pain, while remote reminders can enhance adherence. Only a basic consensus on rehabilitation interventions can be summarized due to design differences. Future research should focus on conducting rigorous trials to provide more conclusive evidence.</description>
    </item>
    <item>
      <title>#8 [65/100] Phase II Prospective Trial of Personalized Radiotherapy Fractionation in Human Papillomavirus Positive Oropharyngeal Cancer.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41519405/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41519405/</guid>
      <dc:creator>Caudell J, Echevarria M, Yang G, Kim Y, Kirtane K, Kish J, Muzaffar J, Zahid M, Chung C, Enderling H</dc:creator>
      <pubDate>Thu, 08 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;ðŸ“Œ SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a phase II prospective trial with a moderate sample size (n=57) focusing on personalized radiotherapy for HPV-positive oropharyngeal cancer, which may provide important insights but lacks the robust evidence of larger randomized trials or definitive practice-changing findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Caudell J, Echevarria M, Yang G, Kim Y, Kirtane K, Kish J, Muzaffar J, Zahid M, Chung C, Enderling H&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; International journal of radiation oncology, biology, physics | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.ijrobp.2025.12.053'&gt;10.1016/j.ijrobp.2025.12.053&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-08&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41519405/'&gt;41519405&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: We previously developed a model of pre-treatment growth and on-treatment response dynamics, the proliferation saturation index (PSI) model, which derives the proliferating and radiosensitive proportion of a tumor based on clinically observed net growth prior to therapy. We hypothesized that personalization of fractionation using PSI would increase the percentage of patients achieving a rapid reduction in tumor size during radiotherapy (RT) for early-stage human papillomavirus related squamous cancers of the oropharynx. PATIENTS AND METHODS: In this single center nonrandomized phase 2 single arm trial, 113 patients underwent screening, and 57 patients were consented and enrolled. Pretreatment PSI was calculated, and patients were assigned to 60 - 70 Gy in 30 - 35 fractions given once daily (PSIâ‰¤ 0.75) or 60 - 69.6 Gy in in 50 - 58 fractions given twice daily (PSI&gt;0.75). The primary endpoint of the study was the rate of patients with â‰¥ 32% reduction in tumor volume at 4 weeks of RT, with a planned sample size of 60 patients, with an interim analysis after 49 patients. Secondary end points included locoregional failure (LRF), progression free survival (PFS), and overall survival (OS). RESULTS: A total of 55 patients evaluable for the primary endpoint were consented and enrolled, and 32 (58%; 95% CIâ€¯=â€¯44%-71%) met the primary endpoint of â‰¥ 32% reduction at 4 weeks of RT, meeting criteria for efficacy, leading to early study closure. For the 54 patients evaluable for secondary endpoints, the cumulative incidence of LRF at 2 years was 2% (95% CI: 0-5.8), with a 2-year PFS of 92% (95% CI: 85-100), and a 2 year OS of 96% (95% CI: 91-100). CONCLUSIONS: Personalized RT fractionation based on PSI suggests a promising rate of mid-treatment response with favorable LF, PFS, and OS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCTXXXX.</description>
    </item>
    <item>
      <title>#9 [65/100] Real-world effectiveness and healthcare utilization of nivolumab for advanced head and neck cancer: A real-world population-based descriptive study.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41512430/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41512430/</guid>
      <dc:creator>Dai WF, Nguyen L, Liu N, Chan KK</dc:creator>
      <pubDate>Thu, 08 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;ðŸ“Œ SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study is a large retrospective analysis examining real-world outcomes of nivolumab in advanced head and neck cancer, providing important insights into survival and healthcare utilization, but lacks the rigor of a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Dai WF, Nguyen L, Liu N, Chan KK&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2026.107851'&gt;10.1016/j.oraloncology.2026.107851&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-08&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41512430/'&gt;41512430&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;INTRODUCTION: Nivolumab was the first immunotherapy to have shown efficacy in platinum-resistant recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHNC) in the CheckMate-141 trial. We conducted a population-based retrospective study to examine the survival outcomes and resource utilization of patients with R/M SCCHNC who were treated with nivolumab. METHOD: Patients with R/M SCCHNC were included in the study if they received nivolumab between January 17th 2018 to August 31st 2022 in Ontario, Canada. The primary outcomes, including overall survival (OS) and time-to-treatment discontinuation (TTD), were assessed using Kaplan-Meier. Cox proportional hazard model was used to explore the association between baseline patient characteristics and all-cause death. The incidence of healthcare utilization was estimated using the cumulative incidence function, taking death as a competing event. RESULTS: A total of 498 R/M SCCHNC patients received nivolumab (Mean age 62.9, 78.7Â % male). The median OS was 6.0Â months (95Â % CI: 5.0-7.3) and median time-to-treatment discontinuation was 2.6Â months (95Â % CI: 2.3-3.0). There is no significant OS difference between older patients (ageÂ &gt;Â 75Â years old) and younger patients (p-value 0.73). At 1-year post-nivolumab initiation, the cumulative incidence of emergency department visits is 50.6Â % (95Â % CI: 46.1-55.0Â %) and direct hospitalization is 22.7Â % (19.0-26.6Â %). CONCLUSION: In this real-world study, the survival outcomes of nivolumab were similar to those observed in CheckMate-141 trial. We demonstrated that there is no survival difference between older and younger patients. Furthermore, more than half of patients exaperienced an hospital encounter with the healthcare system, suggesting significant healthcare resource utilization.</description>
    </item>
    <item>
      <title>#10 [65/100] Perioperative Piperacillin/Tazobactam Reduces Early Onset SSI in Preirradiated Patients Undergoing Microvascular Head and Neck Reconstruction.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41508404/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41508404/</guid>
      <dc:creator>Schuderer JG, Hoferer F, Eichberger J, Fiedler M, Gessner A, Bauernfeind S, Gottsauner M, Nieberle F, Maurer M, Meier JK, et al.</dc:creator>
      <pubDate>Thu, 08 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;ðŸ“Œ SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents a large retrospective analysis with a significant finding regarding SSI reduction in a high-risk population, but it lacks the robustness of a randomized controlled trial and is published in a specialty journal.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Schuderer JG, Hoferer F, Eichberger J, Fiedler M, Gessner A, Bauernfeind S, Gottsauner M, Nieberle F, Maurer M, Meier JK, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Head &amp; neck | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/hed.70151'&gt;10.1002/hed.70151&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-08&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41508404/'&gt;41508404&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: Preirradiated patients undergoing microvascular head and neck reconstruction for tumor recurrence or osteoradionecrosis (ORN) face surgical site infection (SSI) rates exceeding 30%. The impact of perioperative extended-spectrum antibiotic coverage remains unclear. This study hypothesizes that calculated prophylaxis with piperacillin/tazobactam reduces early-onset SSI in this high-risk population. METHODS: From a microvascular reconstructed cohort, 161 with prior irradiation were retrospectively identified (tumor, Nâ€‰=â€‰101; ORN, Nâ€‰=â€‰60). SSI risk reduction was compared between patients receiving piperacillin/tazobactam (Nâ€‰=â€‰39) and standard prophylaxis (Nâ€‰=â€‰122). RESULTS: With underlying SSI incidence of 36%, piperacillin/tazobactam showed a fourfold SSI risk reduction (HR 0.24; pâ€‰=â€‰0.002) across the entire cohort and a fivefold reduction in patients with bone resection (HR 0.17; pâ€‰=â€‰0.01). Subgroup analyses confirmed this effect with a sevenfold reduction in tumor patients (HR 0.14; pâ€‰=â€‰0.008) and a threefold reduction in ORN patients (HR 0.29; pâ€‰=â€‰0.04). Extended coverage did not significantly prolong antibiotic treatment times. CONCLUSION: In summary, calculated use of piperacillin/tazobactam in previously irradiated patients requiring microvascular reconstruction appears effective in reducing early-onset SSI.</description>
    </item>
  </channel>
</rss>
